- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Intensity Therapeutics resumes patient dosing in Swiss trial | 2 | Investing.com | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Intensity Therapeutics setzt Patientendosierung in Schweizer Studie fort | - | Investing.com Deutsch | ||
| Mi | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | 105 | PR Newswire | First patients dosed in Switzerland
SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a... ► Artikel lesen | |
| 08.07. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.07. | Intensity Therapeutics Inc.: Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 | 112 | PR Newswire | Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer
Over 200 patients enrolled in completed INT230-6 studies... ► Artikel lesen | |
| 16.06. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Intensity Therapeutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 07.05. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 582 | PR Newswire | Cash and cash equivalents of $10.2 million as of March 31, 2026
Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC")... ► Artikel lesen | |
| 01.05. | Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 27.03. | Intensity Therapeutics Inc.: Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | 237 | PR Newswire | Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second... ► Artikel lesen | |
| 27.03. | Intensity Therapeutics GAAP EPS of -$8.56 misses by $0.69 | 3 | Seeking Alpha | ||
| 27.03. | INTENSITY THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Intensity Therapeutics erhält neues US-Patent für Krebstherapie | 3 | Investing.com Deutsch | ||
| 23.03. | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.03. | Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause | 3 | Benzinga.com | ||
| 12.03. | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | 280 | PR Newswire | Preliminary observations of the INVINCIBLE-4 Study to date showed that five (5) out of seven (7) patients (71.4%) who received INT230-6 prior to standard of care... ► Artikel lesen | |
| 12.03. | Intensity Therapeutics reports early trial data in breast cancer | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics erfüllt wieder NASDAQ-Anforderungen | 10 | Investing.com Deutsch | ||
| 06.03. | Intensity Therapeutics regains Nasdaq compliance | 1 | Investing.com | ||
| 06.03. | Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement | 2 | Seeking Alpha |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,31 % | KI, Onkologie und Rüstung: TeamViewer, BioNTech & Antimony Resources - Ein Mix fürs Portfolio! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Die Börse ist ein Ort der Extreme und wir blicken heute mit TeamViewer, BioNTech und Antimony Resources auf ein Trio, das aus 3 verschiedenen... ► Artikel lesen | |
| NOVAVAX | 7,130 | -0,97 % | Handelsvolumen bei Novavax-Optionen erreicht Mehrmonatshoch | ||
| CRISPR THERAPEUTICS | 41,765 | -1,66 % | 3 Reasons to Buy CRISPR Therapeutics Stock | ||
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,984 | -3,62 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| QIAGEN | 35,965 | -0,55 % | Qiagen: Die Gerüchte gehen in die zweite Runde | Im Januar wurde gemunkelt, Qiagen könnte unmittelbar vor einer Übernahme stehen. Doch am Ende verlief die Sache im Sand. Die Aktie, die damals einen Riesensatz nach oben gemacht hatte, fiel tiefer als... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | -1,58 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | +2,95 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +2,02 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | +1,56 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,150 (-3,06 %) liegt der Kurs bei 4,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.